- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05589688
Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir (ACICLOPTIM)
November 15, 2023 updated by: University Hospital, Toulouse
The number of obese people will reach 50% of the world population by 2035.
Obesity is a chronic disease.
For obese patients, dosage regimens have been determined for patients with a "normal" BMI between 20-30 kg/m2.
Based on plasma and urine concentrations, a pharmacokinetic model will be performed to study in healthy volunteers, the predictive character of lean mass, measured by DEXA, on renal elimination and therefore on acyclovir exposure.
The main objective of this study is to evaluate, in 4 volunteers groups representative of (1) non-obese (18-24.9
kg/m2), (2) overweight (25-29.9
kg/m2), (3) grade 1 obesity (30-34.9
kg/m2) and (4) grade 2 obesity (35-39.9
kg/m2), the predictive nature of lean mass, measured by DEXA, on renal elimination and therefore on acyclovir exposure.
Study Overview
Detailed Description
This study will complement the clinical data on acyclovir in healthy volunteers considering that current knowledge in terms of drugs use in obese subjects is not sufficient to guarantee the efficacy and/or toxicity absence of exposure.
As a consequence, this lack of certainties leads physicians to propose dosages without exceeding a threshold defined according to (i) their experience, (ii) data obtained for BMI < 30 kg/m2 and/or (iii) an approximate criterion derived from the total weight (adjusted weight...).
Acyclovir is a systemic antiviral drug indicated for the treatment of Herpes Simplex virus (HSV) and Varicella Zoster (VZV) mucosal infections at 15 mg/kg/d in three divided doses, or more severe infections (e.g., herpetic meningoencephalitis) at higher dosage regimen (30 to 45 mg/kg/d in three divided doses).
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sarah Baklouti, PharmD
- Phone Number: 05 67 69 03 83
- Email: baklouti.s@chu-toulouse.fr
Study Contact Backup
- Name: Charline DAGUZAN
- Phone Number: 05 61 77 84 90
- Email: daguzan.c@chu-toulouse.fr
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- healthy volunteers with a BMI between 18 and 39,9 kg/m2, divided into 4 groups: 5 non-obese volunteers (BMI between 18 and 24,9 kg/m2), 5 overweight volunteers (BMI between 25 and 29,9 kg/m2), 5 volunteers with grade 1 obesity (BMI between 30 and 34,9 kg/m2) and 5 volunteers with grade 2 obesity (BMI between 35 and 39,9 kg/m2),
- volunteers with a aGFR > 50 ml/min,
- with a good venous pathway for kinetics,
- women on contraception or postmenopausal women,
- person who has given written consent and affiliated with the public health insurance.
Exclusion Criteria:
- volunteers with nephrotoxic co-prescriptions and/or co-prescriptions that would modify the pharmacokinetics of acyclovir like diuretics, NSAIDs or statins,
- having presented serious allergies to a drug (e.g. angioedema...), with large parenchyma insufficiencies (e.g., hepatic insufficiency, heart failure...),
- with diabetes or taking anti-diabetics due to the possible deterioration of renal function in diabetic patients,
- with arterial hypertension or taking antihypertensive drugs due to the possible modification of renal clearance by modification of blood flow,
- drug interactions with acyclovir (H2 receptor antagonists (e.g., Cimetidine), Probenecid, Mycophenolate Mofetil, Lithium, Anti-calcineurins (Ciclosporin, Tacrolimus)),
- volunteers taking anticoagulants,
- hypersensitivity to acyclovir,
- pregnant woman,
- participation in another clinical study in the last two months
- volunteers with ongoing viral HSV/VZV infection treated with acyclovir,
- adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: acyclovir
Subjects take a single dose of 5 mg/kg infused over 1 hour.
|
Subjects will receive a single dose of 5 mg/kg infused over 1 hour.
Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal elimination clearance
Time Frame: Day 1
|
To quantify the relationship between lean body mass, measured by Dual-energy x-ray absorptiometry (DEXA), and the true absolute glomerular filtration rate (GFRa) which is estimated by the renal elimination clearance of acyclovir.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the interindividual variability of acyclovir exposure : lean mass
Time Frame: Day 1
|
To measure lean mass by DEXA on subjects
|
Day 1
|
the interindividual variability of acyclovir exposure : glomerular filtration rate
Time Frame: Day 1
|
A blood sample will be taken for this purpose to assess the renal function of the volunteer by measuring his uremia and his creatinine allowing the calculation of the glomerular filtration rate.
|
Day 1
|
the qualitative compilation of adverse events associated with acyclovir infusion observed and reported by the volunteer.
Time Frame: Day 1, Day 2
|
adverse events reported by volunteers
|
Day 1, Day 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sarah Baklouti, PharmD, University Hospital, Toulouse
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2024
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
October 17, 2022
First Submitted That Met QC Criteria
October 17, 2022
First Posted (Actual)
October 21, 2022
Study Record Updates
Last Update Posted (Estimated)
November 16, 2023
Last Update Submitted That Met QC Criteria
November 15, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/21/0610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Acyclovir
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Completed
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingInvasive Mechanical Ventilation | HSV Throat Reactivation
-
University of WashingtonNational Institutes of Health (NIH)Completed
-
National Center for Research Resources (NCRR)National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
King Edward Medical UniversityCompletedHerpes Virus InfectionPakistan
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHerpes SimplexUnited States
-
Centers for Disease Control and PreventionMinistry of Health, ThailandCompleted
-
National Center for Research Resources (NCRR)University of Alabama at BirminghamCompletedHerpes SimplexUnited States, Canada
-
National Center for Research Resources (NCRR)National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID)Terminated